Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Public ClinicalTrials.gov record NCT04848519. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT04848519
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Emory University
- Other
- Enrollment
- 6 participants
Conditions and interventions
Conditions
- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Locally Advanced Urethral Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Stage IV Bladder Cancer AJCC v8
- Stage IV Renal Pelvis Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
Interventions
- Avelumab Drug
- Nivolumab Drug
- Pembrolizumab Drug
- Propranolol Hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2021
- Primary completion
- Oct 14, 2025
- Completion
- Dec 3, 2026
- Last update posted
- Feb 18, 2026
2021 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04848519, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04848519 live on ClinicalTrials.gov.